Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894486 | 0.76 | KDM4E (0.41) | NPSR1CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL8016489 | 0.73 | NPSR1 (0.44) | NPSR1CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL8016485 | 0.73 | ALDH1A1 (0.42) | NPSR1CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL8020135 | 0.68 | ALDH1A1 (0.40) | NPSR1CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL2384713 | 0.68 | NPSR1 (0.47) | NPSR1CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL6830787 | 0.64 | ALDH1A1 (0.37) | NPSR1CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL6831562 | 0.64 | ALDH1A1 (0.44) | NPSR1CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL239971 | 0.64 | KDM4E (0.50) | NPSR1CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL28253909 | 0.64 | KDM4E (0.50) | NPSR1CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL96680 | 0.64 | HTT (0.48) | NPSR1CYP1A2CYP2C9CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137849-A1 | USE OF A COMPOUND OF THE DIURETICS CLASS FOR TREATING CANCER | AZELEAD (FR) | 2023-05-04 | — | — | US | claimed |
| EP-3579839-A1 | USE OF A COMPOUND OF THE DIURETICS CLASS FOR TREATING CANCER | AZELEAD (FR) | 2019-12-18 | — | — | EP | claimed |
| WO-2018146390-A1 | USE OF A COMPOUND OF THE DIURETICS CLASS FOR TREATING CANCER | AZELEAD (FR) | 2018-08-16 | — | — | WO | claimed |
| WO-2010138661-A1 | NANOPARTICULATE ANTICANCER COMPOSITIONS AND METHODS FOR MAKING THE SAME | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2010-12-02 | — | — | WO | claimed |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | US | claimed |
| US-7524857-B2 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | SANOFI-AVENTIS (FR) | 2009-04-28 | — | — | US | claimed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | claimed |
| US-20230137849-A1 | USE OF A COMPOUND OF THE DIURETICS CLASS FOR TREATING CANCER | AZELEAD (FR) | 2023-05-04 | — | — | US | disclosed |
| EP-3579839-A1 | USE OF A COMPOUND OF THE DIURETICS CLASS FOR TREATING CANCER | AZELEAD (FR) | 2019-12-18 | — | — | EP | disclosed |
| WO-2018146390-A1 | USE OF A COMPOUND OF THE DIURETICS CLASS FOR TREATING CANCER | AZELEAD (FR) | 2018-08-16 | — | — | WO | disclosed |
| EP-2825177-A1 | NOVEL COMBINATIONS FOR TREATING ACUTE MYELOID LEUKAEMIA OR CHRONIC MYELOID LEUKAEMIA | SANOFI (FR) | 2015-01-21 | — | — | EP | disclosed |
| US-20150005253-A1 | NOVEL COMBINATIONS FOR TREATING ACUTE MYELOID LEUKAEMIA OR CHRONIC MYELOID LEUKAEMIA | SANOFI SA (FR) | 2015-01-01 | — | — | US | disclosed |
| EP-1773835-B1 | PYRIDO-PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF FOR TREATING CANCER | SANOFI SA (FR) | 2014-09-24 | — | — | EP | disclosed |
| EP-1556382-A1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
| EP-1556380-A1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
| US-20040122036-A1 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | SANOFI (FR) | 2004-06-24 | — | — | US | disclosed |
| WO-2004041817-A1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004037821-A1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2004-05-06 | — | — | WO | disclosed |
| EP-1385513-A1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | Sanofi-Aventis (FR) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002087575-A1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | SANOFI-SYNTHELABO (FR) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005253-A1 | NOVEL COMBINATIONS FOR TREATING ACUTE MYELOID LEUKAEMIA OR CHRONIC MYELOID LEUKAEMIA | MCL1, FLT3, ABL1 | NPSR1 4587/4885CYP1A2 3695/4885CYP2C9 4597/4885 |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | NPSR1 3306/4885CYP1A2 781/4885CYP2C9 782/4885 |
| US-20040122036-A1 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | DPYD, DHFR, PNPO | NPSR1 3396/4885CYP1A2 70/4885CYP2C9 69/4885 |
| US-20230137849-A1 | USE OF A COMPOUND OF THE DIURETICS CLASS FOR TREATING CANCER | ABCC4, ATP6V1B1, ABCC2 | NPSR1 2063/4885CYP1A2 1033/4885CYP2C9 826/4885 |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | NPSR1 3306/4885CYP1A2 781/4885CYP2C9 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.